FeesSafety
Pluang+
Home/News Feed/Novo Nordisk shares drop nearly 10% after heart drug trial fails to reduce major cardiovascular events.
NVO
$42.35
+$2.16 +5.37%

Novo Nordisk shares drop nearly 10% after heart drug trial fails to reduce major cardiovascular events.

Market News
31 Jul 2026, 14:43 WIB
CNBC
View Source
Bearish
Novo Nordisk shares drop nearly 10% after heart drug trial fails to reduce major cardiovascular events.

Shares of Novo Nordisk fell sharply after the company announced that its late-stage trial for the heart drug ziltivekimab did not significantly reduce major cardiovascular events like heart attack, stroke, or cardiovascular death compared to a placebo. Although the drug showed some biological activity, it failed to achieve the hoped-for clinical benefits. Novo Nordisk's chief scientific officer emphasized that the company remains committed to cardiovascular disease research despite this setback. The stock dropped about 8.6% in Copenhagen and nearly 10% in U.S. premarket trading.

More News (NVO)

Novo Resources to start 2,700m drilling at Tibooburra Gold Project in Q4 2026

Novo Resources to start 2,700m drilling at Tibooburra Gold Project in Q4 2026

Novo Resources announced a ~2,700 meter reverse circulation drilling program at its Tibooburra Gold Project in New South Wales, starting early November 2026. This follows recent surface sampling and mapping, with assays pending. The company is also r...

Market News
Bullish
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App